We will treat cancer by making it “slim down”
The research team led by Prof. Andrea Alimonti has identified a genetic mechanism that lead to dysregulated de novo lipid synthesis for tumorigenesis in prostate as published in a recent article in the journal Nature Genetics.
The research team discovered that genetic amplification and overexpression of PDC subunits and nuclear trans-localization of this complex in tumors result in dys-regulated mitochondrial activity and expression of lipid synthesis genes which coordinately promote de novo lipid synthesis for tumor growth. Genetic and pharmacological inactivation of PDC restrained prostate tumor growth pointing that PDC as a potential target for prostate cancer therapies.
The professor Ian G. Mills from Cambridge University commented in the News & Views in the same issue of Nature Genetics that “This study will greatly enhance understanding of the mechanistic basis for dysregulated lipid metabolism in prostate cancer and should motivate further clinical and preclinical studies”.